Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA^® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

08/06/20	Coherus BioSciences Reports Second Quarter 2020 Financial Results – Second Quarter UDENYCA ® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million – REDWOOD CITY, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and
08/03/20	Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors REDWOOD CITY, Calif. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020 . “We are very pleased to welcome Kimberly Tzoumakas to our Board during this
07/17/20	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , July 17, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 16, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 53,000 shares of
07/16/20	Coherus BioSciences to Report Second Quarter Financial Results on August 6th REDWOOD CITY, Calif. , July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020 . Starting at 4:30 p.m.

View All